From Trial-and-Error to Targeted Success: How Computational Disease Models Can Help Patients and Pharma Companies

▤ Summary

This article argues that computational disease models can help pharma companies move beyond trial-and-error drug development. It explains how these models can better predict target success, identify patient subpopulations, and improve combination-therapy decisions. The piece also highlights the high failure rate and cost of clinical trials as the main reason pharma needs better model-driven prioritization. It frames computational modeling as a way to reduce risk, lower costs, and bring more effective treatments to market.

▦ Linked Companies

CytoReason LTD

$10M to $25M